Figure 2.

Efficacy of immunotherapies in refractory myasthenia gravis (MG) based on quantitative myasthenia gravis score (QMG). (A) Quantitative synthesis of QMG reduction of rituximab, eculizumab, and tacrolimus. (B) Quantitative synthesis of severity index reduction based on QMG of rituximab, eculizumab, tacrolimus, and cladribine [Myasthenia Gravis Composite scale was used for studies of Levine (27) and Rejdak et al. (20). Manual muscle test was used for the study of Anderson et al. (28)]. A random-effect model was used for quantitative synthesis. Note that each therapy relieved the symptom of refractory myasthenia gravis (MG). However, no significant difference in therapeutic efficacy among these therapies. SMD stands for the standard mean difference.